Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "safety"

1230 News Found

Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
Diagnostic Center | August 25, 2023

Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer

SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators


NIH and Exothera partner to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US
News | August 24, 2023

NIH and Exothera partner to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US

NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials


EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema
Drug Approval | August 21, 2023

EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema

LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment


Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma
Drug Approval | August 16, 2023

Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma

ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity


Lonza launches nebula absorbance reader for streamlined Endotoxin and Pyrogen testing
Digitisation | August 09, 2023

Lonza launches nebula absorbance reader for streamlined Endotoxin and Pyrogen testing

The instrument is fully integrated with Lonza’s latest WinKQCLSoftware to enable data integrity compliance, streamline training, and reduce validation burden


Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
Drug Approval | August 05, 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023


Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup
Healthcare | August 05, 2023

Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup

Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes


Syrma SGS acquires majority sake in Johari Digital Healthcare
Digitisation | August 02, 2023

Syrma SGS acquires majority sake in Johari Digital Healthcare

JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices


Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Drug Approval | August 01, 2023

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy


AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive
News | July 29, 2023

AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive

Unfortunate to see PM’s ‘Make in India’ dream being bulldozed